SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 38,100
+500 (1.33%)
Jul 7, 2026, 11:05 AM KST
SK bioscience Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, SK bioscience stock has a consensus rating of "Sell" and an average price target of ₩33,250. The average 1-year stock price forecast is 12.73% lower than the current stock price, while the lowest is ₩25,000 (-34.38%) and the highest is ₩46,000 (+20.73%).
Price Target: ₩33,250 (-12.73%)
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for SK bioscience stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 6 | 6 | 6 | 5 | 5 | 4 |
Financial Forecast
Revenue This Year
720.68B
from 651.37B
Increased by 10.64%
Revenue Next Year
768.52B
from 720.68B
Increased by 6.64%
EPS This Year
-1.15K
from -733.00
EPS Next Year
-941.43
from -1.15K
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 760.0B | ||
| Avg | 720.7B | ||
| Low | 679.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.7% | ||
| Avg | 10.6% | ||
| Low | 4.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1,037.22 | ||
| Avg | -1,150.61 | ||
| Low | -1,272.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |